Aptar Pharma pulled the trigger on a deal for Pharmaxis’ Orbital high payload dry powder inhaler technology, paying $2.5 million for a worldwide license with the same again to follow if it chooses to ...

The flurry of business development activity at Aptar continues. Having made moves for injectable drug delivery and digital therapeutic players in recent weeks, Aptar has now nabbed (PDF) an option on ...

The Food and Drug Administration (FDA) has approved Tyvaso DPI™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension ...

Please provide your email address to receive an email when new articles are posted on . The dry powder formulation of treprostinil studied in BREEZE is in development with a reusable breath-powered ...

Dr. Miguel Divo, a lung specialist at Brigham and Women’s Hospital, sits in an exam room, across from one of his patients with asthma. Joel Rubinstein, a retired psychiatrist, is about to get a ...

The characteristics of an ideal inhaler are based around the design and formulation of the device, patient use and the clinical effect, together with concordance and patient preference. To ensure ...

Please provide your email address to receive an email when new articles are posted on . Almost all of the estimated 1.15 MMT of CO 2 equivalent emissions in 2022 came from metered-dose inhalers. The ...

Neil Minkoff, MD: That’s such an important aspect in terms of balancing what’s right for each patient. I’m going to pull Dr Drummond in here to comment on that further. We started touching on the idea ...